[PDF][PDF] Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind …
HJ Schmoll, D Cunningham, A Sobrero… - Journal of clinical …, 2012 - researchgate.net
HJ Schmoll, D Cunningham, A Sobrero, CS Karapetis, P Rougier, SL Koski, I Kocakova…
Journal of clinical oncology, 2012•researchgate.netPurpose To compare the efficacy of cediranib (a vascular endothelial growth factor receptor
tyrosine kinase inhibitor [VEGFR TKI]) with that of bevacizumab (anti–VEGF-A monoclonal
antibody) in combination with chemotherapy as first-line treatment for advanced metastatic
colorectal cancer (mCRC).
tyrosine kinase inhibitor [VEGFR TKI]) with that of bevacizumab (anti–VEGF-A monoclonal
antibody) in combination with chemotherapy as first-line treatment for advanced metastatic
colorectal cancer (mCRC).
Purpose
To compare the efficacy of cediranib (a vascular endothelial growth factor receptor tyrosine kinase inhibitor [VEGFR TKI]) with that of bevacizumab (anti–VEGF-A monoclonal antibody) in combination with chemotherapy as first-line treatment for advanced metastatic colorectal cancer (mCRC).
researchgate.net